All PlansPrior AuthMedium impact
Kidney Transplantation (CPB 0493, reviewed 2026-07-30)
Aetna·Nephrology, Transplant Surgery, Urology +1 more·Medical Policy
Effective date
Jul 30, 2026
We identified it
Aug 19, 2026
Summary
Aetna updated its kidney transplantation medical policy (CPB 0493) effective July 30, 2026, clarifying medical necessity criteria for kidney transplants, establishing specific eligibility requirements (transplant committee acceptance, age protocol compliance, malignancy screening, infection status, organ function assessments), and designating multiple diagnostic and monitoring tests as experimental/investigational (including gene microarrays, biomarkers, donor-derived cell-free DNA testing). This policy codifies what procedures require prior authorization and what testing cannot be billed as medically necessary.
Action Required
By August 30, 2026: Billing and clinical teams must implement the following changes: (1) Billing team: Update prior authorization requirements in billing system to require documented transplant committee acceptance and verification of all eligibility criteria (age, malignancy screening results, infection status, cardiovascular/pulmonary/hepatic clearance, renal failure severity) BEFORE processing kidney transplant claims. (2) Clinical documentation team: Create checklist for providers performing transplant evaluations to ensure all required documentation is present (Pap smear within 3 years for women, mammography within 2 years, CD4 count >200 for HIV+ patients, undetectable viral load, stable anti-viral therapy >3 months, creatinine clearance values). (3) Coding/Billing team: Deny or obtain reconsideration for any claims including experimental tests: gene microarrays (MMDx-Kidney), cytokine measurements, Clarava, Pleximark, Tuteva, pre-conditioning therapy (immune-adsorption, rituximab), urinary NGAL/L-FABP, FASL mRNA detection, urinary biomarkers (CXCL9, CXCL10, MCP-1), donor-derived cell-free DNA tests (Allosure, Prospera Kidney, VitaGraft products), or AT1 receptor/antibody measurements. (4) Prior authorization staff: Flag for review any transplant requests for patients age >70 with severe comorbidities, active vasculitis, ongoing substance abuse, severe neurological impairment, or untreated coagulation disorders as these are non-covered scenarios. Failure to obtain proper prior authorization documentation will result in claim denials.